Comparative Pharmacology
Head-to-head clinical analysis: ARANESP versus OMONTYS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARANESP versus OMONTYS.
ARANESP vs OMONTYS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aranesp (darbepoetin alfa) is an erythropoiesis-stimulating agent (ESA) that stimulates erythropoiesis by binding to the erythropoietin receptor on erythroid progenitor cells, promoting their survival, proliferation, and differentiation into mature red blood cells.
Erythropoiesis-stimulating agent; synthetic peptide agonist of the erythropoietin receptor (EPOR) that stimulates erythropoiesis in red blood cell precursors.
Initial dose 0.45 mcg/kg intravenously or subcutaneously once weekly; for patients converting from epoetin alfa, see prescribing information for dose conversion.
45 mg subcutaneously once every 4 weeks (monthly) in adults.
None Documented
None Documented
The terminal elimination half-life is approximately 21 hours (range 15-30 hours) in patients with chronic kidney disease following intravenous administration, and 49 hours (range 27-89 hours) after subcutaneous administration. The long half-life allows for less frequent dosing compared to epoetin alfa.
Terminal elimination half-life is approximately 14.5 hours in healthy adults; in hemodialysis patients, half-life is extended to 26.4–29.9 hours, supporting weekly dosing.
Renal clearance accounts for approximately 10% of total body clearance; however, darbepoetin alfa is primarily eliminated via receptor-mediated endocytosis and subsequent intracellular degradation. Less than 5% is excreted unchanged in urine.
Primarily eliminated via the reticuloendothelial system; no significant renal or biliary excretion. The iron component is incorporated into hemoglobin or stored as ferritin/hemosiderin.
Category C
Category C
Erythropoiesis-Stimulating Agent
Erythropoiesis-Stimulating Agent